Eisai Company, Ltd. Announces Commencement of Operations of a New Research Facility at H3 Biomedicine Inc.

Published: Dec 05, 2011

Tokyo, Dec 2, 2011 (JCN Newswire) - Eisai Co. Ltd announced today that the company's U.S. research subsidiary H3 Biomedicine held a ceremony on December 1 (U.S. Eastern Standard Time) in Massachusetts, Cambridge, to mark the official opening and commencement of operations of its new research facility. H3 Biomedicine aims to facilitate drug discovery based on the latest genetic research findings with a view to providing personalized medicine to treat types of cancer for which sufficient treatment options have yet to be established.

Back to news